Transcat, Inc. (NASDAQ:TRNS) Given Consensus Rating of “Hold” by Analysts

Transcat, Inc. (NASDAQ:TRNS) has been assigned an average rating of “Hold” from the five ratings firms that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $111.50.

Several equities research analysts recently commented on the stock. Craig Hallum boosted their price objective on shares of Transcat from $113.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, December 12th. Oppenheimer downgraded shares of Transcat from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 29th. Northland Securities reiterated a “market perform” rating and issued a $85.00 target price (down previously from $110.00) on shares of Transcat in a research note on Wednesday, January 29th. StockNews.com downgraded shares of Transcat from a “hold” rating to a “sell” rating in a research note on Wednesday, February 5th. Finally, HC Wainwright dropped their target price on shares of Transcat from $126.00 to $106.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th.

Insider Activity

In related news, Director Craig D. Cairns acquired 1,200 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was purchased at an average cost of $77.02 per share, with a total value of $92,424.00. Following the completion of the acquisition, the director now directly owns 1,910 shares of the company’s stock, valued at approximately $147,108.20. This trade represents a 169.01 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Conestoga Capital Advisors LLC raised its holdings in shares of Transcat by 17.9% during the third quarter. Conestoga Capital Advisors LLC now owns 907,191 shares of the scientific and technical instruments company’s stock valued at $109,561,000 after purchasing an additional 137,830 shares during the last quarter. Neuberger Berman Group LLC raised its holdings in shares of Transcat by 1.8% during the fourth quarter. Neuberger Berman Group LLC now owns 873,985 shares of the scientific and technical instruments company’s stock valued at $92,415,000 after purchasing an additional 15,723 shares during the last quarter. Champlain Investment Partners LLC raised its holdings in shares of Transcat by 35.7% during the fourth quarter. Champlain Investment Partners LLC now owns 555,650 shares of the scientific and technical instruments company’s stock valued at $58,754,000 after purchasing an additional 146,150 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Transcat by 178.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 518,597 shares of the scientific and technical instruments company’s stock valued at $54,837,000 after purchasing an additional 332,064 shares during the last quarter. Finally, Royce & Associates LP increased its holdings in Transcat by 8.2% during the third quarter. Royce & Associates LP now owns 511,701 shares of the scientific and technical instruments company’s stock valued at $61,798,000 after buying an additional 38,774 shares during the last quarter. 98.34% of the stock is owned by hedge funds and other institutional investors.

Transcat Trading Down 4.5 %

NASDAQ:TRNS opened at $79.85 on Friday. Transcat has a one year low of $73.37 and a one year high of $147.12. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.42 and a quick ratio of 1.98. The company’s 50-day simple moving average is $95.56 and its 200 day simple moving average is $109.02. The firm has a market capitalization of $743.40 million, a P/E ratio of 43.16 and a beta of 0.67.

Transcat (NASDAQ:TRNS) last posted its quarterly earnings data on Monday, January 27th. The scientific and technical instruments company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.38 by $0.07. Transcat had a net margin of 6.22% and a return on equity of 7.23%. During the same quarter last year, the company earned $0.56 EPS. As a group, analysts forecast that Transcat will post 2.3 EPS for the current fiscal year.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.